The knowledge of different biomarkers related to antitumor immunity such as ALDH1A1 that could have an impact on pathologic response in certain BC subtypes and at the same time, are related to antitumor immunity, might help to elucidate which patients are the best candidates for this type of combined therapeutic modalities. The gene discussed is ALDH1A1; the disease is breast cancer.